Literature DB >> 10881687

Comparison of proviral accessory genes between long-term nonprogressors and progressors of human immunodeficiency virus type 1 infection.

T Yamada1, A Iwamoto.   

Abstract

We compared proviral accessory gene sequences (nef, vpu, vpr, vif, rev, tat) of human immunodeficiency virus type 1 (HIV-1) in the peripheral blood mononuclear cells (PBMC) between seven long-term non-progressors (LTNP) and seven progressors. LTNP frequently harbored proviruses with mutated accessory genes, while almost all accessory genes were intact in progressors. Presence of quasispecies in attenuated viruses suggests that they were not just a fossil record of nonreplication proviruses. These attenuated viruses in LTNP may be the source of their strong immune response against HIV-1. Our result might have relevance to a design of potent therapeutic vaccines.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10881687     DOI: 10.1007/s007050050692

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  23 in total

1.  A doxycycline-dependent human immunodeficiency virus type 1 replicates in vivo without inducing CD4+ T-cell depletion.

Authors:  Nicolas Legrand; Gisela J van der Velden; Raphaël Ho Tsong Fang; Marc Douaisi; Kees Weijer; Atze T Das; Bianca Blom; Christel H Uittenbogaart; Ben Berkhout; Mireille Centlivre
Journal:  J Gen Virol       Date:  2012-05-30       Impact factor: 3.891

2.  Validation of a novel secretion modification region (SMR) of HIV-1 Nef using cohort sequence analysis and molecular modeling.

Authors:  Patrick E Campbell; Olexandr Isayev; Syed A Ali; William W Roth; Ming-Bo Huang; Michael D Powell; Jerzy Leszczynski; Vincent C Bond
Journal:  J Mol Model       Date:  2012-05-30       Impact factor: 1.810

3.  The greater than twofold cost of integration for retroviruses.

Authors:  David C Krakauer; Akira Sasaki
Journal:  Proc Biol Sci       Date:  2006-05-07       Impact factor: 5.349

4.  Coreceptor usage, diversity, and divergence in drug-naive and drug-exposed individuals from Malawi, infected with HIV-1 subtype C for more than 20 years.

Authors:  Ishla Seager; Simon A Travers; Michael D Leeson; Amelia C Crampin; Neil French; Judith R Glynn; Grace P McCormack
Journal:  AIDS Res Hum Retroviruses       Date:  2014-07-29       Impact factor: 2.205

5.  Novel, live attenuated simian immunodeficiency virus constructs containing major deletions in leader RNA sequences.

Authors:  Y Guan; J B Whitney; C Liang; M A Wainberg
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

6.  The identification of unique serum proteins of HIV-1 latently infected long-term non-progressor patients.

Authors:  Rachel Van Duyne; Irene Guendel; Kylene Kehn-Hall; Rebecca Easley; Zachary Klase; Chenglong Liu; Mary Young; Fatah Kashanchi
Journal:  AIDS Res Ther       Date:  2010-07-06       Impact factor: 2.250

7.  Meta-analysis to test the association of HIV-1 nef amino acid differences and deletions with disease progression.

Authors:  Ravindra Pushker; Jean-Marc Jacqué; Denis C Shields
Journal:  J Virol       Date:  2010-01-13       Impact factor: 5.103

8.  Effective downregulation of HLA-A*2 and HLA-B*57 by primary human immunodeficiency virus type 1 isolates cultured from elite suppressors.

Authors:  Eric Nou; Yan Zhou; Damaris D Nou; Joel N Blankson
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

9.  Coreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence.

Authors:  Andreas Jekle; Birgit Schramm; Prerana Jayakumar; Verena Trautner; Dominique Schols; Erik De Clercq; John Mills; Suzanne M Crowe; Mark A Goldsmith
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

10.  Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor.

Authors:  Justin R Bailey; Karen O'Connell; Hung-Chih Yang; Yefei Han; Jie Xu; Benjamin Jilek; Thomas M Williams; Stuart C Ray; Robert F Siliciano; Joel N Blankson
Journal:  J Virol       Date:  2008-05-21       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.